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Background
Alzheimer’s disease (AD) is the most common neurode-
generative disorder in the world. As the aging popula-
tion continues to increase globally, treatment of AD and
other age-associated neurodegenerative diseases is
becoming increasingly important, not only from a
human point of view, but also from an economic per-
spective. In recent years, several attempts have been
made to find novel susceptibility genes and pathways
relevant for AD. Particularly genome-wide association
(GWA) and meta-analysis-based studies have identified
several risk variants in different genes, which signifi-
cantly associate with AD. The subsequent mechanistic
characterization of the identified risk genes is extremely
important as it may pave the way for the development
of new biomarkers and intervention approaches.
Materials and methods
Microarray-based global expression and splicing analysis
of AD brain samples (inferior temporal cortex) was con-
ducted to identify novel AD-associated target genes and
pathways. Brain samples were divided into mild, moderate
and severe AD subgroups according to the neurofibrillary
tangle (NFT) pathology (Braak staging) and expression
and splicing changes were analyzed in relation to the dis-
ease severity. Furthermore, the most prominent risk gene
variants identified in the recent GWA and meta-analysis-
based studies were genotyped and used to elucidate the
expression and splicing changes with respect to the risk
gene profiles. a-, b-, and g-secretase activity as well as
soluble b-amyloid (Ab) 42 measurements were performed
from the same tissue samples and used for correlation
analyses. A subset of the identified AD-associated target
genes were further directed to high-throughput RNA
interference (RNAi) in vitro screening to characterize
specific target genes affecting amyloid precursor protein
(APP) processing and Ab generation.
Results
Apart from the already established target genes known
to be differentially expressed in the AD brain, several
novel targets that showed altered expression and/or spli-
cing with respect to disease severity were identified.
Some of these novel targets revealed significant changes
only in the late phase of the AD (Braak stages: V-VI),
such as clusterin and complement factors. Several others
were significantly associated with the NFT and Ab42
changes already in the early phase of the disease (Braak
stages: III-IV) and the differential expression and/or
splicing was further strengthened at the later phases of
the disease (Braak stages V-VI). Only a small portion of
the identified AD-associated target genes revealed
changes in the APP processing and Ab generation after
the RNAi-mediated down-regulation of target gene pro-
ducts in both non-neuronal and neuronal cell lines
over-expressing APP. Detailed characterization of the
target genes affecting APP processing and Ab generation
are currently underway both in in vitro and in vivo
models of AD to unravel the underlying molecular
mechanisms. Furthermore, the relationships between
AD-associated risk gene profiles and the expression and
splicing of specific targets as well as biological pathways
and gene clusters are currently being assessed.
Conclusions
It is expected that the functional genetic approach adopted
here identifies specific molecular targets in AD pathogen-
esis that underlie its clinical manifestations. It is also likely
that new biomarkers will be identified for risk assessment,
early diagnosis, and disease progression.
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